| Circular RNAs in diseases | Lifetime | 24 | CN 10 | 99.63 |
| Cancer-related molecular mechanisms research | Lifetime | 70 | CN 25 | 99.57 |
| MicroRNA in disease regulation | Lifetime | 71 | CN 17 | 99.61 |
| Growth Hormone and Insulin-like Growth Factors | Lifetime | 84 | CN 1 | 99.27 |
| RNA modifications and cancer | Lifetime | 282 | CN 28 | 99.33 |
| Ferroptosis and cancer prognosis | Lifetime | 74 | CN 25 | 98.67 |
| Immune cells in cancer | Lifetime | 118 | CN 10 | 99.17 |
| Regulation of Appetite and Obesity | Lifetime | 100 | CN 2 | 99.13 |
| Pharmacological Effects of Natural Compounds | Lifetime | 135 | CN 38 | 98.73 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 392 | CN 20 | 98.86 |
| Ginseng Biological Effects and Applications | Lifetime | 57 | CN 30 | 98.66 |
| Biochemical Analysis and Sensing Techniques | Lifetime | 182 | CN 5 | 98.45 |
| Adipose Tissue and Metabolism | Lifetime | 467 | CN 12 | 98.77 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 519 | CN 28 | 98.83 |
| Pancreatic function and diabetes | Lifetime | 529 | CN 6 | 98.49 |
| Nanoplatforms for cancer theranostics | Lifetime | 460 | CN 310 | 98.34 |
| Traditional Chinese Medicine Studies | Lifetime | 118 | CN 83 | 96.81 |
| Epigenetics and DNA Methylation | Lifetime | 845 | CN 74 | 98.11 |
| Cancer Mechanisms and Therapy | Lifetime | 228 | CN 29 | 97.59 |
| Biochemical effects in animals | Lifetime | 397 | CN 39 | 97.26 |
| Ion channel regulation and function | Lifetime | 915 | CN 21 | 97.54 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 849 | CN 57 | 97.39 |
| Protein Hydrolysis and Bioactive Peptides | Lifetime | 513 | CN 97 | 97.15 |
| Signaling Pathways in Disease | Lifetime | 329 | CN 13 | 96.49 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 746 | CN 18 | 97.00 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 423 | CN 31 | 96.37 |
| Traditional Chinese Medicine Analysis | Lifetime | 294 | CN 230 | 95.88 |
| Tryptophan and brain disorders | Lifetime | 761 | CN 21 | 96.69 |
| Cancer-related gene regulation | Lifetime | 913 | CN 125 | 96.00 |
| Metabolism, Diabetes, and Cancer | Lifetime | 937 | CN 23 | 96.93 |
| Sirtuins and Resveratrol in Medicine | Lifetime | 226 | CN 34 | 95.22 |
| Diet, Metabolism, and Disease | Lifetime | 916 | CN 31 | 96.11 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 593 | CN 28 | 96.03 |
| Lipid metabolism and disorders | Lifetime | 390 | CN 11 | 95.88 |
| Inflammasome and immune disorders | Lifetime | 574 | CN 57 | 95.22 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 946 | CN 48 | 95.60 |
| Ovarian function and disorders | Lifetime | 850 | CN 27 | 96.64 |
| High-Voltage Power Transmission Systems | Lifetime | 311 | CN 189 | 95.01 |
| interferon and immune responses | Lifetime | 989 | CN 121 | 94.93 |
| Bioactive Compounds and Antitumor Agents | Lifetime | 627 | CN 33 | 94.25 |
| Thyroid Disorders and Treatments | Lifetime | 729 | CN 9 | 95.70 |
| Hypothalamic control of reproductive hormones | Lifetime | 486 | CN 4 | 95.24 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 962 | CN 49 | 93.50 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 196 | CN 9 | 92.81 |
| Medicinal Plant Pharmacodynamics Research | Lifetime | 197 | CN 127 | 87.82 |
| Apelin-related biomedical research | Lifetime | 428 | CN 29 | 90.56 |
| Medicinal Plants and Bioactive Compounds | Lifetime | 239 | CN 72 | 88.85 |
| Selenium in Biological Systems | Lifetime | 829 | CN 132 | 91.58 |
| Nuclear Receptors and Signaling | Lifetime | 786 | CN 50 | 90.83 |
| Cardiac Fibrosis and Remodeling | Lifetime | 860 | CN 94 | 90.69 |
| Phagocytosis and Immune Regulation | Lifetime | 995 | CN 78 | 88.49 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 911 | CN 27 | 87.45 |
| Environmental and Agricultural Sciences | Lifetime | 904 | CN 814 | 87.46 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 898 | CN 115 | 87.57 |
| Inflammation biomarkers and pathways | Lifetime | 305 | CN 41 | 85.34 |
| Forest, Soil, and Plant Ecology in China | Lifetime | 690 | CN 637 | 81.06 |
| Caveolin-1 and cellular processes | Lifetime | 860 | CN 41 | 83.51 |
| Macrophage Migration Inhibitory Factor | Lifetime | 750 | CN 41 | 83.17 |
| Berberine and alkaloids research | Lifetime | 827 | CN 291 | 80.51 |
| Biological and pharmacological studies of plants | Lifetime | 774 | CN 380 | 74.19 |
| Technology and Security Systems | Lifetime | 298 | CN 266 | 64.46 |
| Andrographolide Research and Applications | Lifetime | 468 | CN 118 | 58.08 |
| Immune cells in cancer | 2021-2025 | 5 | CN 3 | 99.82 |
| MicroRNA in disease regulation | 2021-2025 | 4 | CN 2 | 99.86 |
| RNA modifications and cancer | 2021-2025 | 12 | CN 7 | 99.85 |
| Circular RNAs in diseases | 2021-2025 | 6 | CN 2 | 99.74 |
| Epigenetics and DNA Methylation | 2021-2025 | 20 | CN 7 | 99.11 |
| Cancer-related molecular mechanisms research | 2021-2025 | 31 | CN 23 | 99.63 |
| Ginseng Biological Effects and Applications | 2021-2025 | 3 | CN 2 | 99.17 |
| Natural product bioactivities and synthesis | 2021-2025 | 10 | CN 3 | 98.86 |
| Ferroptosis and cancer prognosis | 2021-2025 | 40 | CN 29 | 99.17 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 5 | CN 1 | 97.18 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 43 | CN 19 | 98.21 |
| Immunotherapy and Immune Responses | 2021-2025 | 84 | CN 21 | 98.48 |
| Lipid metabolism and disorders | 2021-2025 | 10 | CN 1 | 98.52 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 31 | CN 19 | 97.18 |
| Immune Cell Function and Interaction | 2021-2025 | 189 | CN 43 | 97.17 |
| Adipose Tissue and Metabolism | 2021-2025 | 108 | CN 24 | 96.51 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 407 | CN 68 | 98.41 |
| Metabolomics and Mass Spectrometry Studies | 2021-2025 | 119 | CN 35 | 96.12 |
| Nanoplatforms for cancer theranostics | 2021-2025 | 262 | CN 226 | 98.21 |
| Reproductive Biology and Fertility | 2021-2025 | 152 | CN 34 | 97.12 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 530 | CN 57 | 97.61 |
| Anesthesia and Neurotoxicity Research | 2021-2025 | 55 | CN 16 | 95.30 |
| Inflammasome and immune disorders | 2021-2025 | 109 | CN 53 | 95.37 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 230 | CN 73 | 95.68 |
| Phagocytosis and Immune Regulation | 2021-2025 | 42 | CN 15 | 93.17 |
| Ovarian function and disorders | 2021-2025 | 116 | CN 19 | 96.67 |
| Cancer-related gene regulation | 2021-2025 | 110 | CN 72 | 93.83 |
| RNA Interference and Gene Delivery | 2021-2025 | 247 | CN 133 | 95.92 |
| Chronic Disease Management Strategies | 2021-2025 | 166 | CN 13 | 94.63 |
| Inflammatory mediators and NSAID effects | 2021-2025 | 39 | CN 5 | 93.62 |
| Autophagy in Disease and Therapy | 2021-2025 | 162 | CN 82 | 94.37 |
| Growth Hormone and Insulin-like Growth Factors | 2021-2025 | 71 | CN 4 | 95.73 |
| Thyroid Cancer Diagnosis and Treatment | 2021-2025 | 150 | CN 25 | 95.95 |
| Diet and metabolism studies | 2021-2025 | 620 | CN 74 | 94.40 |
| RNA Research and Splicing | 2021-2025 | 381 | CN 110 | 92.58 |
| interferon and immune responses | 2021-2025 | 191 | CN 104 | 92.32 |
| Extracellular vesicles in disease | 2021-2025 | 451 | CN 275 | 93.72 |
| Intensive Care Unit Cognitive Disorders | 2021-2025 | 357 | CN 27 | 94.21 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 191 | CN 20 | 93.96 |
| Regulation of Appetite and Obesity | 2021-2025 | 73 | CN 4 | 93.28 |
| Advanced biosensing and bioanalysis techniques | 2021-2025 | 966 | CN 682 | 95.29 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 775 | CN 94 | 94.97 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 200 | CN 35 | 90.14 |
| Endoplasmic Reticulum Stress and Disease | 2021-2025 | 175 | CN 31 | 88.77 |
| Immune Response and Inflammation | 2021-2025 | 219 | CN 86 | 89.17 |
| Fatty Acid Research and Health | 2021-2025 | 137 | CN 32 | 90.88 |
| Genomics, phytochemicals, and oxidative stress | 2021-2025 | 133 | CN 40 | 90.19 |
| Osteoarthritis Treatment and Mechanisms | 2021-2025 | 368 | CN 118 | 92.64 |
| Birth, Development, and Health | 2021-2025 | 657 | CN 77 | 91.92 |
| Cancer Mechanisms and Therapy | 2021-2025 | 173 | CN 68 | 90.18 |
| Peptidase Inhibition and Analysis | 2021-2025 | 495 | CN 142 | 91.42 |
| Photodynamic Therapy Research Studies | 2021-2025 | 207 | CN 116 | 91.53 |
| Sleep and related disorders | 2021-2025 | 439 | CN 37 | 92.87 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 376 | CN 52 | 89.60 |
| Trace Elements in Health | 2021-2025 | 230 | CN 83 | 89.08 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 661 | CN 59 | 91.06 |
| Medicinal Plant Pharmacodynamics Research | 2021-2025 | 16 | CN 15 | 85.32 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 182 | CN 43 | 86.21 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 184 | CN 41 | 87.53 |
| Sulfur Compounds in Biology | 2021-2025 | 152 | CN 118 | 90.61 |
| Cancer Treatment and Pharmacology | 2021-2025 | 528 | CN 44 | 90.14 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 700 | CN 278 | 86.54 |
| Hepatitis B Virus Studies | 2021-2025 | 716 | CN 136 | 89.63 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 170 | CN 49 | 85.43 |
| Inflammation biomarkers and pathways | 2021-2025 | 35 | CN 15 | 85.00 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 180 | CN 69 | 87.05 |
| Diet, Metabolism, and Disease | 2021-2025 | 539 | CN 95 | 87.54 |
| Elbow and Forearm Trauma Treatment | 2021-2025 | 247 | CN 9 | 87.45 |
| Pancreatic function and diabetes | 2021-2025 | 846 | CN 48 | 88.14 |
| Signaling Pathways in Disease | 2021-2025 | 97 | CN 29 | 82.22 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 633 | CN 111 | 85.32 |
| Frailty in Older Adults | 2021-2025 | 902 | CN 92 | 88.23 |
| Healthcare Systems and Reforms | 2021-2025 | 383 | CN 49 | 86.97 |
| Tissue Engineering and Regenerative Medicine | 2021-2025 | 571 | CN 177 | 85.73 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 437 | CN 116 | 84.67 |
| Kruppel-like factors research | 2021-2025 | 114 | CN 30 | 84.66 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 497 | CN 203 | 80.83 |
| Protein Hydrolysis and Bioactive Peptides | 2021-2025 | 909 | CN 472 | 86.17 |
| Chemotherapy-induced organ toxicity mitigation | 2021-2025 | 93 | CN 5 | 82.46 |
| Food Quality and Safety Studies | 2021-2025 | 356 | CN 257 | 83.60 |
| Biochemical Analysis and Sensing Techniques | 2021-2025 | 646 | CN 249 | 81.68 |
| Educational Reforms and Innovations | 2021-2025 | 86 | CN 50 | 76.39 |
| Biochemical effects in animals | 2021-2025 | 421 | CN 245 | 80.36 |
| Retinoids in leukemia and cellular processes | 2021-2025 | 196 | CN 47 | 78.97 |
| Traditional Chinese Medicine Analysis | 2021-2025 | 341 | CN 307 | 79.04 |
| Infant Nutrition and Health | 2021-2025 | 697 | CN 205 | 81.10 |
| Advanced Glycation End Products research | 2021-2025 | 297 | CN 128 | 78.56 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 455 | CN 47 | 79.22 |
| Heme Oxygenase-1 and Carbon Monoxide | 2021-2025 | 311 | CN 130 | 78.01 |
| Spectroscopy Techniques in Biomedical and Chemical Research | 2021-2025 | 869 | CN 349 | 81.18 |
| Folate and B Vitamins Research | 2021-2025 | 513 | CN 140 | 76.37 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 287 | CN 113 | 76.41 |
| Mesoporous Materials and Catalysis | 2021-2025 | 496 | CN 230 | 79.59 |
| Head and Neck Anomalies | 2021-2025 | 189 | CN 57 | 78.75 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 625 | CN 139 | 76.11 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 101 | CN 27 | 72.84 |
| Alcohol Consumption and Health Effects | 2021-2025 | 869 | CN 106 | 76.93 |
| Melanoma and MAPK Pathways | 2021-2025 | 579 | CN 37 | 76.56 |
| S100 Proteins and Annexins | 2021-2025 | 435 | CN 74 | 72.52 |
| Traditional Chinese Medicine Studies | 2021-2025 | 302 | CN 220 | 74.28 |
| Selenium in Biological Systems | 2021-2025 | 572 | CN 262 | 75.70 |
| Berberine and alkaloids research | 2021-2025 | 177 | CN 107 | 72.51 |
| Dietary Effects on Health | 2021-2025 | 682 | CN 93 | 71.69 |
| Alkaloids: synthesis and pharmacology | 2021-2025 | 301 | CN 123 | 67.55 |
| Telomeres, Telomerase, and Senescence | 2021-2025 | 614 | CN 82 | 68.21 |
| Fluoride Effects and Removal | 2021-2025 | 375 | CN 156 | 68.05 |
| Connexins and lens biology | 2021-2025 | 384 | CN 113 | 65.65 |
| Galectins and Cancer Biology | 2021-2025 | 920 | CN 272 | 64.62 |
| Chemotherapy-related skin toxicity | 2021-2025 | 294 | CN 12 | 62.21 |
| Sodium Intake and Health | 2021-2025 | 780 | CN 112 | 61.97 |
| Biological and pharmacological studies of plants | 2021-2025 | 324 | CN 263 | 62.30 |
| NF-κB Signaling Pathways | 2021-2025 | 311 | CN 119 | 58.64 |
| Adenosine and Purinergic Signaling | 2021-2025 | 969 | CN 239 | 61.14 |
| Plant-based Medicinal Research | 2021-2025 | 396 | CN 286 | 60.34 |
| Andrographolide Research and Applications | 2021-2025 | 107 | CN 26 | 56.36 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 327 | CN 88 | 58.68 |
| Medicinal Plants and Bioactive Compounds | 2021-2025 | 369 | CN 157 | 58.94 |
| Nuclear Receptors and Signaling | 2021-2025 | 625 | CN 143 | 56.57 |
| Traditional Chinese Medicine and Integrative Care | 2021-2025 | 283 | CN 185 | 58.73 |
| Ginger and Zingiberaceae research | 2021-2025 | 677 | CN 235 | 54.76 |
| Insurance, Mortality, Demography, Risk Management | 2021-2025 | 554 | CN 123 | 54.19 |
| Apelin-related biomedical research | 2021-2025 | 409 | CN 87 | 54.93 |
| Surface Chemistry and Catalysis | 2021-2025 | 793 | CN 330 | 50.96 |
| Ideological and Political Education | 2021-2025 | 163 | CN 132 | 50.19 |
| Cell death mechanisms and regulation | 2021-2025 | 806 | CN 238 | 47.14 |
| Renin-Angiotensin System Studies | 2021-2025 | 641 | CN 67 | 42.46 |
| Medicinal Plant Extracts Effects | 2021-2025 | 174 | CN 25 | 40.95 |
| Microbial metabolism and enzyme function | 2021-2025 | 552 | CN 144 | 32.57 |